Recorded fact · drug.label_indication
drug.label_indication for regorafenib|metastatic-colorectal-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 4357b5c7 resolves to.
The record
| Fact id | 4357b5c79da7a4c7636f7f03 |
|---|---|
| Entity | drug: regorafenib|metastatic-colorectal-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260209 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR th
Shown with dashes as hyphens. SHA-256 of the exact stored quote: da88b04da8ca1293c84bbafbc28d2ab8bd91f5cba8129637433f66fe033b6a13.
The value
{
"ingredient": "Regorafenib",
"conditionId": "metastatic-colorectal-cancer",
"conditionName": "Metastatic Colorectal Cancer",
"matchedAlias": "Metastatic colorectal cancer",
"context": "indication",
"brand": "Stivarga",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "824f19c9-0546-4a8a-8d8f-c4055c04f7c7",
"labelEffectiveTime": "20260209",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: abf713ebdb1549157fb044328fa488db1d3d2497ce3cd5f319a096a65d5d43d6.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.